Loading…
Invicta Diagnostic (INVICTA)₹73.55+6.44%Healthcare Service Provider
In the Mar 2026 quarter (consolidated), Invicta Diagnostic reported sales of ₹15.38 Cr and net profit of ₹0.78 Cr. For the year to Mar 2026, sales were ₹32.29 Cr and net profit ₹4.87 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2025 | Mar 2026 | |
|---|---|---|
| Sales | 16.92 | 15.38 |
| Expenses | 10.20 | 12.43 |
| Operating Profit | 6.75 | 2.98 |
| OPM % | 39.8% | 19.4% |
| Other Income | 0.12 | 0.55 |
| Interest | 0.11 | 0.10 |
| Depreciation | 1.38 | 1.89 |
| Profit before tax | 5.41 | 1.59 |
| Tax % | 24.7% | 50.0% |
| Net Profit | 4.07 | 0.78 |
| EPS (Rs) | 4.31 | 0.71 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 7.45 | 7.98 | 30.06 | 32.29 |
| Expenses | 4.21 | 4.60 | 21.10 | 22.59 |
| Operating Profit | 3.23 | 3.39 | 8.99 | 9.75 |
| OPM % | 43.4% | 42.5% | 29.9% | 30.2% |
| Other Income | 0.00 | 0.34 | 0.56 | 0.68 |
| Interest | 0.03 | 0.09 | 0.24 | 0.21 |
| Depreciation | 0.96 | 0.99 | 2.50 | 3.26 |
| Profit before tax | 2.28 | 2.68 | 6.85 | 7.02 |
| Tax % | 22.9% | 0.0% | 31.6% | 30.4% |
| Net Profit | 1.75 | 2.68 | 4.68 | 4.87 |
| EPS (Rs) | — | 204.17 | 5.56 | 3.90 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 0.13 | 8.44 | 12.61 |
| Reserves | 12.07 | 8.42 | 37.46 |
| Borrowings | 1.88 | 1.68 | 3.69 |
| Other Liabilities | 1.79 | 2.77 | 6.69 |
| Total Liabilities | 15.87 | 21.31 | 60.45 |
| Fixed Assets | 11.80 | 9.64 | 19.25 |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 4.34 | 6.21 |
| Other Assets | 4.07 | 7.33 | 34.99 |
| Inventories | 0.38 | 0.49 | 0.58 |
| Trade receivables | 0.83 | 1.47 | 0.58 |
| Cash & equivalents | 1.35 | 2.17 | 22.22 |
| Total Assets | 15.87 | 21.31 | 60.45 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | 4.20 | 6.46 | 2.92 |
| Cash from investing activity | −9.99 | −5.21 | −13.63 |
| Cash from financing activity | 7.13 | −0.41 | 30.74 |
| Net cash flow | 1.35 | 0.84 | 20.06 |
| Capex | 12.74 | 0.54 | 12.92 |
| Free cash flow | −8.55 | 6.14 | −9.92 |
| CFO / OP % | 123.9% | 71.9% | 39.9% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 38 | 19 | 7 |
| Inventory days | 297 | 83 | 79 |
| Days payable | 1,103 | 70 | 254 |
| Cash conversion cycle | −768 | 32 | −168 |
| Working capital days | 6 | 22 | 56 |
| ROCE % | — | 46.4% | 20.2% |
For the Mar 2026 quarter, Invicta Diagnostic reported sales of ₹15.38 Cr and net profit of ₹0.78 Cr. The operating margin was 19.4%.
Invicta Diagnostic's sales for the year to Mar 2026 were ₹32.29 Cr.
Net profit for the year to Mar 2026 was ₹4.87 Cr. Earnings per share over the same trailing period were ₹3.90.
Invicta Diagnostic reported borrowings of ₹3.69 Cr at Mar 2026, against cash and equivalents of ₹22.22 Cr.
Cash from operations was ₹2.92 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹9.92 Cr.